Skip to main content
    F

    Fate Therapeutics Inc (FATE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.14
    -0.14 (-10.94%)

    Market Cap: $155.74M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Fate Therapeutics Inc (FATE) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Fate Therapeutics are Lineage Cell Therapeutics (LCTX), Protara Therapeutics (TARA) and Invivyd (IVVD). By market cap, Fate Therapeutics ranks 7th of the 13 companies on this page; Fulcrum Therapeutics (FULC) is the largest at $287.96M.

    Peer Comparison

    FATE's ROIC of -51.3% is above the peer median of -74.1%, and its revenue growth of 9.2% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Fate Therapeutics (FATE)$155.74MN/A29.7x0.0%-51.3%9.2%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Armata Pharmaceuticals Inc (ARMP)$143.94MN/A14.7x0.0%-184.6%173.6%0.00%
    Foghorn Therapeutics Inc (FHTX)$124.12M40.1x1.1x8.4%N/A925.0%0.00%
    Cellectis SA (CLLS)$118.86MN/A1.8x0.0%-74.1%-85.4%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    Sutro Biopharma (STRO)$163.03MN/A3.4x0.0%N/A-6.1%0.00%
    OUTLOOK THERAPEUTICS INC (OTLK)$100.54MN/AN/A0.0%-776.9%-99.4%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Peer median$154.96M40.1x3.1x0.0%-74.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Fate Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Armata Pharmaceuticals Inc (ARMP)
    Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment...
    ARMP competitors
    Foghorn Therapeutics Inc (FHTX)
    Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within...
    FHTX competitors
    Cellectis SA (CLLS)
    Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors...
    CLLS competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    Sutro Biopharma (STRO)
    Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company.
    STRO competitors
    OUTLOOK THERAPEUTICS INC (OTLK)
    Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic...
    OTLK competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors

    Frequently Asked Questions About FATE

    Who are Fate Therapeutics' main competitors?

    The companies most similar to Fate Therapeutics include Lineage Cell Therapeutics (LCTX), Protara Therapeutics (TARA), Invivyd (IVVD), Compass Therapeutics (CMPX) and Fulcrum Therapeutics (FULC), listed from the closest match.

    Who is Fate Therapeutics' biggest competitor?

    Fulcrum Therapeutics (FULC) is the largest of the similar companies at $287.96M; Lineage Cell Therapeutics (LCTX) is the closest match by business profile, size, sector and industry.

    How does FATE stock compare with its competitors?

    FATE's P/S is 29.7x against a peer median of 3.1x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Fate Therapeutics' competitors pays a higher dividend?

    Fate Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Fate Therapeutics bigger than its competitors?

    No. Fate Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Fulcrum Therapeutics (FULC) at $287.96M.